Next |
home / stock / sonn / sonn message board
Subject | By | Source | When |
---|---|---|---|
WTF, is this an auction? I'll take.25s | Pnypnchr | investorshub | 06/28/2023 9:04:25 PM |
I love selected accounting myself.. $SONN | Carjockey2 | investorshub | 06/28/2023 7:58:53 PM |
Never see you posting on those stocks combined | Carjockey2 | investorshub | 06/28/2023 7:58:08 PM |
LMAO Not for me, it isn't sunshine... Funny how | Carjockey2 | investorshub | 06/28/2023 7:56:57 PM |
Off to where? 22% down. | jonestint | investorshub | 06/28/2023 7:53:27 PM |
I want .35s if possible | starkd748 | investorshub | 06/28/2023 7:43:18 PM |
This is the dip that people waiting for | SecondLife | investorshub | 06/28/2023 6:28:27 PM |
exercise price of $0.6749 per share, are exercisable | tw0122 | investorshub | 06/28/2023 6:24:08 PM |
Load em cheapies .. The warrants will have | tw0122 | investorshub | 06/28/2023 6:23:32 PM |
Thats what happened | crazy horse 0 | investorshub | 06/28/2023 5:23:56 PM |
$SONN News! Sonnet BioTherapeutics, Inc. | SecondLife | investorshub | 06/28/2023 3:13:19 PM |
Looking good limer814 | Golden Cross | investorshub | 06/28/2023 3:08:07 PM |
And we're off!!!! | Carjockey2 | investorshub | 06/28/2023 3:07:32 PM |
Whats the catalyst? | slowd | investorshub | 06/28/2023 2:54:59 PM |
Nice! I'll scoop up more if it drops | SecondLife | investorshub | 06/28/2023 2:54:16 PM |
Move your bid up.. | Carjockey2 | investorshub | 06/28/2023 2:53:34 PM |
Sometimes it's just that easy.. $SONN | Carjockey2 | investorshub | 06/28/2023 2:52:24 PM |
The whole family's going 10 of us and | Carjockey2 | investorshub | 06/28/2023 2:49:36 PM |
My 49s and 51s are looking good rt now | limer814 | investorshub | 06/28/2023 2:48:45 PM |
Nice place!! | limer814 | investorshub | 06/28/2023 2:48:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase...
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology . SON-1010, Sonnet's lea...